日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

RESONATE-2 研究的最终分析:对慢性淋巴细胞白血病/小淋巴细胞淋巴瘤一线伊布替尼治疗进行长达 10 年的随访。

Burger, Jan A; Barr, Paul M; Robak, Tadeusz; Owen, Carolyn; Tedeschi, Alessandra; Sarma, Anita; Patten, Piers E M; Grosicki, Sebastian; McCarthy, Helen; Offner, Fritz; Szafer-Glusman, Edith; Zhou, Cathy; Szoke, Anita; Neumayr, Lynne; Dean, James P; Ghia, Paolo; Kipps, Thomas J

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

T-bet抑制慢性淋巴细胞白血病中恶性B细胞的增殖

Roessner, Philipp M; Seufert, Isabelle; Chapaprieta, Vicente; Jayabalan, Ruparoshni; Briesch, Hannah; Massoni-Badosa, Ramon; Boskovic, Pavle; Benckendorff, Julian; Roider, Tobias; Arseni, Lavinia; Coelho, Mariana; Chakraborty, Supriya; Vaca, Alicia M; Sivina, Mariela; Muckenhuber, Markus; Rodriguez-Rodriguez, Sonia; Bonato, Alice; Herbst, Sophie A; Zapatka, Marc; Sun, Clare; Kretzmer, Helene; Naake, Thomas; Bruch, Peter-Martin; Czernilofsky, Felix; Ten Hacken, Elisa; Schneider, Martin; Helm, Dominic; Yosifov, Deyan Y; Kauer, Joseph; Danilov, Alexey V; Bewarder, Moritz; Heyne, Kristina; Schneider, Christof; Stilgenbauer, Stephan; Wiestner, Adrian; Mallm, Jan-Philipp; Burger, Jan A; Efremov, Dimitar G; Lichter, Peter; Dietrich, Sascha; Martin-Subero, José I; Rippe, Karsten; Seiffert, Martina

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD

在接受伊布替尼治疗的慢性淋巴细胞白血病(CLL)患者中,氘代水标记:白血病细胞动力学与IGHV、ZAP-70和微小残留病(MRD)相关。

Kim, Ekaterina; Chen, Shih-Shih; Sivina, Mariela; Hwang, Hyunsoo; Huang, Xuelin; Ferrajoli, Alessandra; Jain, Nitin; Wierda, William G; Wodarz, Dominik; Chiorazzi, Nicholas; Burger, Jan A

First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis

一线伊布替尼治疗慢性淋巴细胞白血病患者的总生存率与年龄匹配的一般人群相似:一项汇总的事后分析

Ghia, Paolo; Owen, Carolyn; Allan, John N; Barrientos, Jacqueline C; Barr, Paul M; Shi, Chunxue; Szoke, Anita; Abbazio, Christopher; Krigsfeld, Gabriel S; Burger, Jan A

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

一项针对慢性淋巴细胞白血病里氏转化患者的维奈托克治疗的多中心研究

Hampel, Paul J; Swaminathan, Mahesh; Rogers, Kerry A; Parry, Erin M; Burger, Jan A; Davids, Matthew S; Ding, Wei; Ferrajoli, Alessandra; Hyak, Jonathan M; Jain, Nitin; Kenderian, Saad S; Wang, Yucai; Wierda, William G; Woyach, Jennifer A; Parikh, Sameer A; Thompson, Philip A

Estimating the Number of Polygenic Diseases Among Six Mutually Exclusive Entities of Non-Tumors and Cancer

估算六种互斥的非肿瘤和癌症实体中多基因疾病的数量

Smith, C I Edvard; Burger, Jan A; Zain, Rula

Mathematical multi-compartment modeling of chronic lymphocytic leukemia cell kinetics under ibrutinib

伊布替尼治疗下慢性淋巴细胞白血病细胞动力学的数学多室模型

Schulz, Melanie; Bleser, Sanne; Groels, Manouk; Bošnački, Dragan; Burger, Jan A; Chiorazzi, Nicholas; Marr, Carsten

Chronic Lymphocytic Leukemia: Disease Biology

慢性淋巴细胞白血病:疾病生物学

Koehrer, Stefan; Burger, Jan A

Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity

伊布替尼治疗慢性淋巴细胞白血病患者的长期疗效:重点关注高血压和心血管毒性

Gordon, Max J; Jones, Jade E; George, Binsah; Peterson, Christine; Burger, Jan A; Jain, Nitin; Keating, Michael; Wierda, William G; Durand, Jean-Bernard; Ferrajoli, Alessandra

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

RESONATE-2 研究中接受伊布替尼治疗 ≥5 年的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的特征和临床结局

Woyach, Jennifer A; Barr, Paul M; Kipps, Thomas J; Barrientos, Jacqueline C; Ahn, Inhye E; Ghia, Paolo; Girardi, Vincent; Hsu, Emily; Jermain, Mandy; Burger, Jan A